Protagonist Therapeutics and Janssen’s Collaboration Offers Hope for Oral Therapy for IL-23-Mediated Diseases
May 13, 2023
Trending News ☀️
Protagonist Therapeutics ($NASDAQ:PTGX), a clinical stage biopharmaceutical company, has announced a collaboration with Janssen, a subsidiary of Johnson & Johnson, to develop oral therapies for IL-23-mediated diseases. This collaboration reflects the potential of an oral treatment for diseases associated with IL-23 pathways. The therapy aims to modulate the immune system to treat chronic inflammatory diseases such as Crohn’s Disease, ulcerative colitis, and psoriasis. It could prove to be a more convenient alternative to current treatments, which may involve injections or infusions. The collaboration also promises to bring positive financial returns for Protagonist Therapeutics.
In addition, Protagonist Therapeutics is also eligible to receive tiered royalties on any commercial product. This could provide a major boost in revenue for the company. The collaboration between Protagonist Therapeutics and Janssen is a major step forward in the development of treatments for IL-23-mediated diseases. This agreement bodes well for the future of oral therapies that target these conditions, and could provide relief for many patients who currently require frequent injections and infusions.
Market Price
On Friday, Protagonist Therapeutics saw a 2.6% increase in its stock price from its last closing price. It opened at $25.0 and closed at $25.4. This increase can be attributed to the recent collaboration between Protagonist Therapeutics and Janssen, a Johnson & Johnson’s Pharmaceuticals Company. This collaboration is in order to develop an oral therapy for interleukin-23 (IL-23)-mediated diseases.
The therapy will target the IL-23 receptor, which is responsible for the activation of inflammatory pathways that cause numerous diseases. This collaboration offers a potential solution to the challenges posed by these diseases and provides hope to those suffering from them. The collaboration between Protagonist Therapeutics and Janssen is an exciting development in the field of therapeutics and could prove to be an effective treatment for IL-23-mediated diseases. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Protagonist Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.86 | -140.19 | -16319.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Protagonist Therapeutics. More…
| Operations | Investing | Financing |
| -108.14 | 91.47 | 18.84 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Protagonist Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 239.86 | 23.69 | 4.19 |
Key Ratios Snapshot
Some of the financial key ratios for Protagonist Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -28.2% | – | -16566.1% |
| FCF Margin | ROE | ROA |
| -12681.3% | -41.3% | -37.1% |
Analysis
At GoodWhale, we recently conducted an analysis of PROTAGONIST THERAPEUTICS‘s financials. After taking a look at the numbers, we’ve determined that PROTAGONIST THERAPEUTICS is a medium risk investment in terms of financial and business aspects. We identified 4 risk warnings in the income sheet, balance sheet, cashflow statement, and financial journal. As a registered user, you can have full access to these warnings so you can make an informed decision when deciding if PROTAGONIST THERAPEUTICS is the right investment for you. Our findings will help you understand the potential risks associated with this company’s overall financial performance. At GoodWhale, we are committed to providing you with the latest financial insights so you can make the best investment decisions. We strive to be your trusted source for reliable financial information. More…
Peers
The company’s competitors include LogicBio Therapeutics Inc, Landos Biopharma Inc, and IO Biotech Inc.
– LogicBio Therapeutics Inc ($NASDAQ:LOGC)
LogicBio Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. The company’s lead product candidate is LB-1001, which is in clinical development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company has a market cap of $67.57 million and a return on equity of -82.33%. LogicBio Therapeutics is headquartered in Boston, Massachusetts.
– Landos Biopharma Inc ($NASDAQ:LABP)
Landos Biopharma Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
Landos Biopharma Inc has a market cap of 14.4M as of 2022, a Return on Equity of -64.92%. The company is dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in oncology. The company has a market capitalization of $72.04 million and a negative return on equity of 20.77%. Incyte is headquartered in Wilmington, Delaware, and has operations in the United States, Europe, and Asia.
Summary
Protagonist Therapeutics, Inc. (PTGX) is a clinical-stage biopharmaceutical company focused on developing novel oral peptide-based therapeutics to treat serious and life-threatening diseases, such as inflammatory bowel disease (IBD), hepatitis B virus infection and cancer. Through this collaboration, Protagonist and Janssen will jointly identify, develop, and commercialize oral therapy candidates for the treatment of IL-23-mediated diseases, including ulcerative colitis and Crohn’s disease. This agreement could potentially strengthen Protagonist’s position in the market and unlock greater value for its investors.
